Abstract

Cervical cancer remains a significant global health challenge, predominantly caused by persistent infection with high-risk strains of the human papillomavirus (HPV). The advent of HPV vaccination has introduced a transformative approach to preventing this malignancy, offering the potential to reduce its incidence worldwide. This article explores the role of HPV vaccination in cervical cancer prevention, examining its efficacy, global implementation, and impact on disease burden. Through a review of clinical data, vaccination programs, and epidemiological trends, the article highlights how HPV vaccines have contributed to declining cervical cancer rates in vaccinated populations. It also addresses challenges such as vaccine accessibility, public awareness, and disparities in coverage, particularly in low- and middle-income countries. The findings underscore the vaccine’s critical role as a primary prevention tool and advocate for expanded efforts to achieve global health equity in cervical cancer reduction.